Hayley Crawford, PhD
application scientist
molecular integrals
Sheila Keating, Ph.D.
Vice President, Immunology
gigagen
Dr. Natalie Anosova
Director, Immunology
Head of Preclinical Immunobiology
Sanofi
Broadcast Date: November 10, 2022
Weather: 8:00 a.m. Pacific Time, 11:00 a.m. Eastern Time, 5:00 p.m. CET
The COVID-19 pandemic has put virology at the forefront of many research agendas. But how do we stay ahead of the next viral threat? Limited commercial laboratories are licensed to conduct research on BSL-3 or BSL-4 pathogens. However, reporter virus tools, such as ready-to-use reporter virus particles (RVPs, i.e. pseudoviruses), have enabled the investigation of viruses in a BSL-2 environment, allowing sera and antibodies to be tested in assays. Safe, high-yield neutralization to accelerate virology. research.
In this GEN webinar, one of our distinguished speakers, Dr. Hayley Crawford, will discuss Integral Molecular’s extensive RVP catalog, including influenza A and B, Marburg virus, and the latest variants of SARS-CoV-2. In addition, he will talk about Integral Molecular’s experience in custom RVP projects. Additionally, the panelists Dr. Sheila Keating Y Dr. Natalie Anosova will describe how Integral Molecular’s extensive collection of SARS-CoV-2 RVP variants enabled them to comply with the latest FDA guidance for therapeutic antibody and vaccine variant testing.
Join us to learn more about how RVPs have enabled therapeutic research during the COVID-19 pandemic and how they can enhance virology research on current and emerging viral targets.
A live Q&A session will follow the presentation, giving you the opportunity to pose questions to our expert panelists.
Produced with the support of:
Source: news.google.com